Short Sellers Have Mixed Feelings on Major Pharma
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
ThinkstockTuesday turned out to be a seriously ugly day for the stock market. By some counts it was even uglier than Monday’s sloppy session due to how it closed on the lows…
thinkstockAugust 25, 2015: Markets opened higher on Tuesday and the markets quickly shook of the remaining effects of Monday’s tank job. WTI crude oil gained 2.8% ahead of Wednesday’s report on inventories,…
Some investors are looking at value stocks, and others are going defensive. The stocks that have limited business cycles are a great focus for investors in a time of worry.
thinkstockAugust 20, 2015: Markets opened lower on Thursday and things got worse from there. The bad news started in China, where equities lost 3.4% in Shanghai. Rumors that Greek Prime Minister Tsipras…
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in…
thinkstockAugust 13, 2015: Markets opened slightly higher on Thursday following reassurances from the People’s Bank of China that it is nearly finished tinkering with the country’s currency and that the bank is…
Thursday's top analyst upgrades, downgrades and initiations include Alibaba, Baker Hughes, GoPro, Merck, Microsoft and Yahoo.
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
In a new report, UBS made changes in the firm's Equity Focus list and updated other positions.
Ebola fears have subsided and the development of a vaccine or related drugs has been put on the back burner for most, but one biotech made waves in the market Monday morning.
thinkstockJuly 29, 2015: Markets opened higher on Wednesday and two of the three major indexes spend all day trading above the break-even line; only the Nasdaq Composite took a brief visit into…
ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part the resulting…
ThinkstockMerck & Co. Inc. (NYSE: MRK) reported its second-quarter financial results Tuesday before the markets opened. The pharmaceutical giant had $0.86 in earnings per share (EPS) on $9.8 billion in revenue compared…